MedTrace Logo

Vaccination of High Risk Breast Cancer Patients

NCT01390064 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-08-20

Study results available
· View outcomes & findings →

Summary

Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.

Conditions

  • Stage IV Breast Cancer

Interventions

BIOLOGICAL

Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG

All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Laura Hutchins, MD · University of Arkansas

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2018-07-31
Completion
2019-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01390064 on ClinicalTrials.gov